Gelteq Limited (NASDAQ:GELS) Short Interest Up 453.2% in June

Gelteq Limited (NASDAQ:GELS) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 426,471 shares, a growth of 453.2% from the May 31st total of 77,097 shares. Currently, 4.0% of the company’s stock are short sold. Based on an average daily volume of 19,813,187 shares, the days-to-cover ratio is currently 0.0 days.

Gelteq Stock Up 5.5%

Shares of GELS stock traded up $0.03 on Friday, reaching $0.63. The stock had a trading volume of 87,415 shares, compared to its average volume of 11,233,403. Gelteq has a 12 month low of $0.39 and a 12 month high of $2.02. The firm’s 50-day moving average is $0.63 and its two-hundred day moving average is $0.77.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Gelteq has an average rating of “Sell”.

Institutional Trading of Gelteq

A hedge fund recently bought a new position in Gelteq stock. Susquehanna International Group LLP acquired a new stake in Gelteq Limited (NASDAQ:GELS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned about 0.44% of Gelteq as of its most recent SEC filing.

Gelteq Company Profile

Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.